Literature DB >> 23503574

Detection of underlying malignancy in patients with paraneoplastic neurological syndromes: comparison of 18F-FDG PET/CT and contrast-enhanced CT.

N Schramm1, A Rominger, C Schmidt, J N Morelli, C Schmid-Tannwald, F G Meinel, M F Reiser, C Rist.   

Abstract

PURPOSE: To determine the value of combined (18)F-FDG PET/CT with diagnostic contrast-enhanced CT (CECT) in detecting primary malignancies and metastases in patients with paraneoplastic neurological syndromes (PNS) and to compare this with CECT alone.
METHODS: PET/CT scans from 66 patients with PNS were retrospectively evaluated. Two blinded readers initially reviewed the CECT portion of each PET/CT scan. In a second session 3 months later, the readers analysed the combined PET/CT scans. Findings on each study were assessed using a four-point-scale (1 normal/benign; 2 inconclusive, further diagnostic work-up may be necessary; 3 malignant; 4 inflammatory). Sensitivity and specificity for malignant findings were calculated for PET/CT and CECT. Interreader agreement was determined by calculating Cohen's kappa. Pooled data from clinical follow-up (including histopathology and follow-up imaging, median follow-up 20.0 months) served as the reference gold standard.
RESULTS: Both readers classified 12 findings in ten patients (15%) as malignant on the PET/CT scans (two patients had two primary tumours). One such imaging finding (suspected thymic cancer) was false-positive (i.e. benign histology). The most common tumours were bronchial carcinoma (n = 3), lymph node metastases of gynaecological tumours (n = 3) and tonsillar carcinoma (n = 2). Three of 12 findings (25%) were not detected by CECT alone (cervical carcinoma, lymph node metastasis and tonsillar carcinoma). In a per-patient analysis, sensitivity and specificity for malignant findings were 100% and 90% for PET/CT and 78% and 88% for CECT. In 24% (reader 1) and 21% (reader 2) of the patients, the PET/CT findings were inconclusive. Of these findings, 57% (reader 1) and 56% (reader 2) were only diagnosed with PET (e.g. focal FDG uptake of the thyroid, gastrointestinal tract and ovaries). On follow-up, none of these findings corresponded to malignancy. Overall agreement between the two readers was excellent with a Cohen's kappa of 0.95 ± 0.04 (p < 0.001) for PET/CT and 0.97 ± 0.03 (p < 0.001) for CECT alone.
CONCLUSION: In this cohort of patients with PNS, PET/CT exhibited improved detection of underlying malignancy versus CECT alone. While hybrid imaging produces a greater number of inconclusive findings, sensitivity is increased for the detection of head and neck and gynaecological malignancies as well as metastatic lymph node involvement.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23503574     DOI: 10.1007/s00259-013-2372-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  32 in total

1.  Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients.

Authors:  F Graus; F Keime-Guibert; R Reñe; B Benyahia; T Ribalta; C Ascaso; G Escaramis; J Y Delattre
Journal:  Brain       Date:  2001-06       Impact factor: 13.501

Review 2.  Paraneoplastic syndromes involving the nervous system.

Authors:  Robert B Darnell; Jerome B Posner
Journal:  N Engl J Med       Date:  2003-10-16       Impact factor: 91.245

3.  PET scan in clinically suspected paraneoplastic neurological syndromes: a 6-year prospective study in a regional neuroscience unit.

Authors:  M Hadjivassiliou; S J Alder; E J R Van Beek; M B Hanney; E Lorenz; D G Rao; B Sharrack; W B Tindale
Journal:  Acta Neurol Scand       Date:  2008-10-06       Impact factor: 3.209

4.  Update on paraneoplastic neurologic disorders.

Authors:  Myrna R Rosenfeld; Josep Dalmau
Journal:  Oncologist       Date:  2010-05-17

Review 5.  Role of PET/CT in gynecological tumors based on the revised FIGO staging classification.

Authors:  Tetsuya Tsujikawa; Tatsuro Tsuchida; Yoshio Yoshida; Tetsuji Kurokawa; Yasushi Kiyono; Hidehiko Okazawa; Hirohiko Kimura
Journal:  Clin Nucl Med       Date:  2011-09       Impact factor: 7.794

6.  Strategies in detection of the primary tumour in anti-Yo associated paraneoplastic cerebellar degeneration.

Authors:  Markus Frings; Gerald Antoch; Philipp Knorn; Lutz Freudenberg; Ulrich Bier; Dagmar Timmann; Matthias Maschke
Journal:  J Neurol       Date:  2005-02       Impact factor: 4.849

7.  Management of paraneoplastic neurological syndromes: report of an EFNS Task Force.

Authors:  C A Vedeler; J C Antoine; B Giometto; F Graus; W Grisold; I K Hart; J Honnorat; P A E Sillevis Smitt; J J G M Verschuuren; R Voltz
Journal:  Eur J Neurol       Date:  2006-07       Impact factor: 6.089

8.  Recommended diagnostic criteria for paraneoplastic neurological syndromes.

Authors:  F Graus; J Y Delattre; J C Antoine; J Dalmau; B Giometto; W Grisold; J Honnorat; P Sillevis Smitt; Ch Vedeler; J J G M Verschuuren; A Vincent; R Voltz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

9.  Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis.

Authors:  Rainer Linke; Mira Schroeder; Thomas Helmberger; Raymond Voltz
Journal:  Neurology       Date:  2004-07-27       Impact factor: 9.910

10.  FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes.

Authors:  S Younes-Mhenni; M F Janier; L Cinotti; J C Antoine; F Tronc; V Cottin; P J Ternamian; P Trouillas; J Honnorat
Journal:  Brain       Date:  2004-09-10       Impact factor: 13.501

View more
  8 in total

1.  Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry.

Authors:  Rathan M Subramaniam; Anthony F Shields; Archana Sachedina; Lucy Hanna; Fenghai Duan; Barry A Siegel; Bruce E Hillner
Journal:  Oncologist       Date:  2016-07-08

2.  [Radiological diagnostics in CUP syndrome].

Authors:  P M Kazmierczak; K Nikolaou; A Rominger; A Graser; M F Reiser; C C Cyran
Journal:  Radiologe       Date:  2014-02       Impact factor: 0.635

Review 3.  18F-fluorodeoxyglucose positron emission tomography in the diagnosis of malignancy in patients with paraneoplastic neurological syndrome: a systematic review and meta-analysis.

Authors:  Ana María García Vicente; Roberto C Delgado-Bolton; Mariano Amo-Salas; Jesús López-Fidalgo; Ana Paula Caresia Aróztegui; José Ramón García Garzón; Javier Orcajo Rincón; María José García Velloso; María de Arcocha Torres; Soledad Alvárez Ruíz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-27       Impact factor: 9.236

4.  Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients.

Authors:  Stine Bjørn Kristensen; Søren Hess; Henrik Petersen; Poul Flemming Høilund-Carlsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-21       Impact factor: 9.236

5.  Utility of 18F-FDG-PET/CT in patients suspected of paraneoplastic neurological syndrome: importance of risk classification.

Authors:  F J Pena Pardo; A M García Vicente; M Amo-Salas; J F López-Fidalgo; J A Garrido Robles; J Á de Ayala Fernández; P Del Saz Saucedo; M Muñoz Pasadas; A Soriano Castrejón
Journal:  Clin Transl Oncol       Date:  2016-05-02       Impact factor: 3.405

6.  The Utility of FDG-PET/CT in Clinically Suspected Paraneoplastic Neurological Syndrome: A Literature Review and Retrospective Case Series.

Authors:  Mark P Maskery; Jonathan Hill; John R Cain; Hedley C A Emsley
Journal:  Front Neurol       Date:  2017-06-01       Impact factor: 4.003

7.  Diagnostic Value of Positron Emission Tomography Combined with Computed Tomography for Evaluating Critically Ill Neurological Patients.

Authors:  Knut Kurt William Kampe; Roman Rotermund; Milena Tienken; Götz Thomalla; Marc Regier; Susanne Klutmann; Stefan Kluge
Journal:  Front Neurol       Date:  2017-02-14       Impact factor: 4.003

8.  18F-fluorodeoxyglucose positron emission tomography/ computed tomography in the diagnosis of suspected paraneoplastic syndromes: A retrospective analysis.

Authors:  Richard Bresler; Harry William Schroeder; David Z Chow; Ruth Lim
Journal:  World J Nucl Med       Date:  2020-01-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.